LL-37 dosage: reported doses and schedule

A human defense peptide with mixed topical wound-trial results and no established injection regimen.

Also called: LL37, Cathelicidin LL-37, hCAP18/LL-37.

Anti-inflammatory and antimicrobial peptides · Human cathelicidin antimicrobial and immune-signaling peptide.

Typical reported dose: 100–125 mcg once a day

  • First wound trial: 0.5 mg/mL: 0.5 mg/mL LL-37 applied to the ulcer twice weekly for 4 weeks. twice weekly, on the skin. Studied in a trial. Studied in: Adults with hard-to-heal venous leg ulcers. (source)
  • First wound trial: 1.6 mg/mL: 1.6 mg/mL LL-37 applied to the ulcer twice weekly for 4 weeks. twice weekly, on the skin. Studied in a trial. Studied in: Adults with hard-to-heal venous leg ulcers. (source)
  • First wound trial: 3.2 mg/mL: 3.2 mg/mL LL-37 applied to the ulcer twice weekly for 4 weeks. twice weekly, on the skin. Studied in a trial. Studied in: Adults with hard-to-heal venous leg ulcers. (source)
  • HEAL: 0.5 mg/mL: 0.5 mg/mL at 25 microlitres/cm², giving 12.5 mcg/cm² per application. twice weekly, every 3 ± 1 days, on the skin. Studied in a trial. Studied in: Adults with hard-to-heal venous ulcers receiving compression. (source)
  • HEAL: 1.6 mg/mL: 1.6 mg/mL at 25 microlitres/cm², giving 40 mcg/cm² per application. twice weekly, every 3 ± 1 days, on the skin. Studied in a trial. Studied in: Adults with hard-to-heal venous ulcers receiving compression. (source)
  • Foot-ulcer cream: 0.5 mg/g: 0.5 mg/g cream; 0.025 mL cream/cm² of wound, twice weekly for 4 weeks. twice weekly, on the skin. Studied in a trial. Studied in: Adults with mildly infected diabetic foot ulcers. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Related to LL-37

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.